Myovant Sciences is a biopharmaceutical company. Co. has two U.S. Food and Drug Administration-approved products, which consist of: ORGOVYX® (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with prostate cancer; and MYFEMBREE® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), an oral GnRH treatment for the management of heavy menstrual bleeding associated with uterine fibroids. Co.'s MYFEMBREE is being evaluated for contraceptive ability in women with heavy menstrual bleeding associated with uterine fibroids or endometriosis-associated pain who are 18 to 50 years of age and at risk for pregnancy. The MYOV average annual return since 2016 is shown above.
The Average Annual Return on the MYOV average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MYOV average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MYOV average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free MYOV Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
